Literature DB >> 24646855

High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies.

Inmaculada Castillo1, Jorge Martinez-Ara2, Teresa Olea2, Javier Bartolomé1, Rosario Madero3, Eduardo Hernández4, Carmen Bernis5, Ana Aguilar2, Juan A Quiroga1, Vicente Carreño1, Rafael Selgas6.   

Abstract

The association of hepatitis C virus (HCV) infection and glomerulonephritis is well known. However, the relationship between immune-mediated glomerulonephritis and occult HCV, characterized by the presence of HCV-RNA in liver or in peripheral blood mononuclear cells in the absence of serological markers, is unknown. We tested this in 113 anti-HCV-negative patients; 87 with immune-mediated glomerulonephritis and 26 controls with hereditary glomerular nephropathies. All patients were serum HCV-RNA negative by conventional real-time PCR. Significantly, occult HCV-RNA (detectable viral RNA in peripheral blood mononuclear cells or in serum after ultracentrifugation) was found in 34 of 87 patients with immune-mediated glomerulonephritis versus 1 of 26 control patients. The serum creatinine levels were significantly higher in patients with immune-mediated glomerulonephritis with than in those without occult HCV (1.5 versus 1.1 mg/dl, respectively). A multivariate analysis adjusted for gender showed a significantly increased risk of occult HCV in patients with immune-mediated glomerulonephritis versus the controls (odds ratio of 13.29). Progression to end-stage renal disease tended to be faster in patients with immune-mediated glomerulonephritis and occult HCV than in the negative cases. Thus, occult HCV is strongly associated with immune-mediated glomerulonephritis and may have a role in the progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24646855     DOI: 10.1038/ki.2014.68

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

Review 2.  Hepatitis C and kidney disease: An overview and approach to management.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Hepatol       Date:  2015-01-27

Review 3.  Hepatitis C and its impact on renal transplantation.

Authors:  Jose M Morales; Fabrizio Fabrizi
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

Review 4.  Occult HCV Infection: The Current State of Knowledge.

Authors:  Mohammad Saeid Rezaee-Zavareh; Reza Hadi; Hamidreza Karimi-Sari; Mohammad Hossein Khosravi; Reza Ajudani; Fardin Dolatimehr; Mahdi Ramezani-Binabaj; Seyyed Mohammad Miri; Seyed Moayed Alavian
Journal:  Iran Red Crescent Med J       Date:  2015-11-29       Impact factor: 0.611

5.  Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease - a nationwide cohort study.

Authors:  Ming-Shyan Lin; Tien-Hsing Chen; Wey-Yil Lin; Chi-Hung Liu; Yung-Yu Hsieh; Wen-Nan Chiu; Chih-Hsiang Chang; Mei-Yen Chen; Chang-Min Chung; Yu-Sheng Lin
Journal:  BMC Gastroenterol       Date:  2017-08-16       Impact factor: 3.067

Review 6.  Occult Hepatitis C Virus Infection: A Review.

Authors:  Alyssa Austria; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

7.  Recurrence of Cryoglobulinemia Secondary to Hepatitis C in a Patient with HCV RNA (-) Negative in the Serum.

Authors:  Małgorzata Sikorska-Wiśniewska; Katarzyna Sikorska; Anna Wróblewska; Tomasz Liberek; Agnieszka Perkowska-Ptasińska; Alicja Dębska-Ślizień
Journal:  Case Rep Nephrol Dial       Date:  2021-06-14

Review 8.  A New Twist to a Chronic HCV Infection: Occult Hepatitis C.

Authors:  Bashar M Attar; David Van Thiel
Journal:  Gastroenterol Res Pract       Date:  2015-06-24       Impact factor: 2.260

9.  High prevalence of occult hepatitis C infection in predialysis patients.

Authors:  Luís Henrique Bezerra Cavalcanti Sette; Edmundo Pessoa de Almeida Lopes; Nathália Campello Guedes Dos Anjos; Lucila Maria Valente; Sávio Augusto Vieira de Oliveira; Norma Lucena-Silva
Journal:  World J Hepatol       Date:  2019-01-27

10.  Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.

Authors:  Ali Nada; Mohamed Abbasy; Aliaa Sabry; Azza Mohamed Abdu Allah; Somaia Shehab-Eldeen; Nada Elnaidany; Hanan Elimam; Kawthar Ibraheem Mohamed Ibraheem; Abdallah Essa
Journal:  Can J Gastroenterol Hepatol       Date:  2020-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.